Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)-Reference-Cited by-同舟云学术

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)

Published:2020-06-24 Issue:10 Volume:42 Page:2852-2862
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Yen Chia‐Jui¹,Kiyota Naomi²³^ORCID,Hanai Nobuhiro⁴,Takahashi Shunji⁵,Yokota Tomoya⁶,Iwae Shigemichi⁷,Shimizu Yasushi⁸,Hong Ruey‐Long⁹,Goto Masahiro¹⁰,Kang Jin‐Hyoung¹¹,Li Wing Sum Kenneth¹²,Ferris Robert L.¹³^ORCID,Gillison Maura¹⁴,Endo Toshimitsu¹⁵^ORCID,Jayaprakash Vijayvel¹⁶,Tahara Makoto¹⁷

Affiliation:

1. Division of Hematology and Oncology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan

2. Department of Medical Oncology and Hematology Kobe University Hospital Kobe Japan

3. Cancer Center Kobe University Hospital Kobe Japan

4. Department of Head and Neck Surgery Aichi Cancer Center Hospital Nagoya Japan

5. Department of Medical Oncology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

6. Division of Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan

7. Department of Head and Neck Surgery Hyogo Cancer Center Akashi Japan

8. Department of Medical Oncology Hokkaido University Hospital Sapporo Japan

9. Department of Oncology National Taiwan University Hospital Taipei Taiwan

10. Cancer Chemotherapy Center Osaka Medical College Hospital Takatsuki Japan

11. Division of Medical Oncology, Department of Internal Medicine The Catholic University of Korea, Seoul St. Mary's Hospital Seoul Republic of Korea

12. Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China

13. UPMC Hillman Cancer Center University of Pittsburgh Medical Center Cancer Center Pittsburgh Pennsylvania USA

14. Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine MD Anderson Cancer Center Houston Texas USA

15. Section 1, Oncology Medical Affairs ONO Pharmaceutical Co., Ltd Osaka Japan

16. Oncology Clinical Development BMS, Bristol‐Myers Squibb Princeton New Jersey USA

17. Department of Head and Neck Medical Oncology National Cancer Center Hospital East Kashiwa Japan

Funder

Ono Pharmaceutical

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26331

Reference36 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013

3. Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009

4. Trends in Head and Neck Cancer in South Korea Between 1999 and 2012

5. Increasing incidence of oral cancer in Hong Kong—Who, where…and why?

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy;Oral Diseases;2024-01-04

2. 口腔がんの薬物療法;Japanese Journal of Oral and Maxillofacial Surgery;2023-08-20

3. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline;Journal of Clinical Oncology;2023-02-10

4. Immunotherapy for Head and Neck Cancers;Handbook of Cancer and Immunology;2023

5. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy;International Immunopharmacology;2022-12